Is There A Drug For COVID-19?
You’re probably talking about remdesivir, an experimental anti-viral drug associated with a modest reduction in recovery time for patients infected with coronavirus in the U.S. A study in China has found no such benefit.
According to preliminary findings from the National Institutes of Health, patients treated with remdesivir recovered 31% faster than those who received a placebo, and 11 days recovery time for patients treated with placebo improved compared to 15 days. The study also revealed that those treated with remdesivir are less likely to die.
This new piece of information was supported by the National Institute for Allergy and Infectious Diseases (NIAID) and included 1,063 hospitalized COVID-19 patients with lung involvement. Recovery among the participants was described as good enough to be discharged from the hospital and return to their normal activities.
Remdesivir is defined as “research broad spectrum antiviral”.
It was first used in clinical trials during the Ebola outbreak in 2014. Treatment includes a 10-day injection. NIAID director M.D. Dr. While explaining the study results, Anthony Fauci said he was optimistic that the drug would be the “standard of care” for patients with COVID-19.
However, the time for these results to be published was criticized by some of the leading scientists because it was made public before being published in a peer review or medical journal. Still, according to the New York Times, the U.S. Food and Drug Administration seems to announce emergency approval for remdesivir for COVID-19 treatment.
Although Remdesivir appears to speed up the healing of some COVID-19 patients, keep in mind that it is used only in research studies and is not licensed or approved in the U.S. for the treatment of infection in this article.
Andrew Weil, M.D.